European Antibiotic Awareness Day turns 18: What have we learnt so far?
on November 18, 2026
-
Contributors
Manuela Gialanella -
Experts
Christian Giske, Pablo Moral -
Categories
Articles, Health -
Tags
antibiotics, resistance, antimicrobial, amr, infections, bacteriophages, microbiology, healthcare, policy, europe -
Share this
Since the discovery of bacterial infections in the first half of the 20th century, humanity has relied on the great healing capabilities of antibiotics as a cornerstone of modern medicine - perhaps too heavily. Excessive antibiotic consumption has accelerated antimicrobial resistance (AMR) in bacteria, a phenomenon now responsible for around 35.000 deaths annually in the European Union and the European Economic Area. This toll is comparable to the combined impact of influenza, tuberculosis and HIV/AIDS.
Long gone are the days when a simple dentist visit could be a life-threatening adventure. Today, we just take prophylactic antibiotics to keep bacteria from infecting our open wounds, possibly causing sepsis. The same applies to post-surgical therapies, and to most bacterial-caused sicknesses. Antibiotics set the scenery for a medical fairytale that seemed to emancipate humanity from some of its longest-standing pathogens.
But bacteria are living creatures, subject to the same laws of natural selection that drive evolution.
By excessively consuming antibiotics, communities can act as natural - better said artificial - selection agents. Antibiotic misuse, especially with overprescription or with incomplete treatments, has turned them into a breeding ground for resistance.
Dr Pablo Moral, AMR expert working on finding new antibiotic treatments within the EU-funded project END2AMR: “Evolution and adaptation to the environment cannot be stopped. We cannot halt evolution: we have to assume that it will keep going and bacteria will continue to change. […] This is why within END2AMR, we focus on new targets and entirely new mechanisms of action that also allow us to study and address resistance from very early stages and to explore innovative ways to tackle resistance mechanismsfrom different perspectives at the same time. Contrasting bacteria from multiple angles at the same time is very important.” - Read the full interview with Pablo Moral
Finding new antibiotic options is a crucial part of the solution, as new pathways can help bypass resistance mechanisms. For this reason, Dr Moral and his colleagues at END2AMR aim to develop novel therapeutic approaches beyond conventional antibiotics. Among other options they are exploring lysins produced by bacteriophages - viruses that specialise in killing bacteria - as possible therapeutic tools: “Lysins' main role is to break down bacterial cell walls, and destruct the bacteria in what is known as “lytic death”. Lysins are therefore a promising new antibiotic tool.”
Five targets for antimicrobial consumption and resistance by 2030
Research also needs the support of communities and decision makers. When combatting antimicrobial resistance, we all have a role to play: no single player can solve this pressing global health issue alone. This is the reason why, in 2023, a European Council recommendation on tackling antimicrobial resistance was adopted. It outlines five targets for antimicrobial consumption and resistance to be reached by 2030 in a One Health approach. As compared with baseline year 2019, the EU should:
- Reduce the total consumption of antibiotics in its population by 20%;
- Ensure that at least 65% of the total consumption of antibiotics in humans comes from the 'Access' group of antibiotics. “Access antibiotics” are molecules that have a narrow spectrum of activity and a good safety profile in terms of side effects, as per the WHO AWaRe classification.
- Reduce infections caused by meticillin-resistant Staphylococcus aureus (MRSA) by 15%;
- Reduce infections caused by third-generation cephalosporin-resistant Escherichia coli (E. coli) by 10%;
- Reduce infections caused by carbapenem-resistant Klebsiella pneumoniae (K. pneumoniae) by 5%.
Dr Christian Giske, Head of Antimicrobial Resistance and Healthcare-Associated Infections at the European Centre for Disease Prevention and Control (ECDC), explains that surveillance data show improvement for some of the targets, especially those related to Staphylococcus aureus, but that we are still far from reaching all the set goals.
The most recent ECDC reports show that some countries face greater challenges than others in achieving different goals: “Regarding AMR specifically, we can see that it continues to rise across the European Union and the European Economic Area: this is consistent with the most recent, currently unpublished, data as well.” Dr Christian Giske explains that the ECDC continuously monitors surveillance data on AMR and antimicrobial consumption in Member States to keep track of the progress towards the five targets set by the Council for 2030: “Unfortunately, for some of the pathogens under surveillance there are concerns with increasing resistance.”
European Antibiotic Awareness Day
As researchers and policymakers push forward in the fight against antimicrobial resistance, it is particularly important for communities to take a stance too, especially in countries such as Italy, Greece, Cyprus and Romania, which share some of the heavier burdens. Key measures include advocating for and adopting responsible practices, such as avoiding antibiotic consumption without a prescription or ensuring their correct use when necessary. Basic hygiene, like washing hands to avoid spreading infections, remains the gold standard too.
This is why the European Centre for Disease Prevention and Control (ECDC) established the European Antibiotic Awareness Day (EEAD) in 2008 to promote awareness. Today, 18 November 2026, marks the 18th anniversary of this initiative. As this important day comes of age, the organisers chose to focus on antibiotics consumption in children:
Dr Christian Giske, Head of Antimicrobial Resistance and Healthcare-Associated Infections at the European Centre for Disease Prevention and Control (ECDC): “This year, we are focusing on children - particularly infants and preschool-aged children, because they are heavily exposed to antibiotics, often without need: many common childhood infections do not require antibiotics. That is why, if we were able to reduce antibiotic use in this group of patients, it could be a big factor in the overall discussion about how to reduce consumption.”- Read the full interview with Christian Giske
Research, policymaking, surveillance and community engagement together form the backbone of an integrated approach to counter antimicrobial resistance. Without it, we risk the unthinkable: a regression nearly a century back, where bacterial infections were frequently deadly, and global health prospects were far worse. As Dr. Giske puts it: “AMR is really a joint responsibility, no single level can be entirely responsible. Policymakers, governmental and non-governmental organisations, practitioners, parents and patients all have a role to play.”
As with all global challenges, it is hard to see how much of a difference our individual contributions can make. However, when it comes to antimicrobial resistance, the power is literally in our (thoroughly washed) hands.
Related content: